About this trial
The incidence of lung cancer in China is increasing year by year. Currently, the treatment primarily based on video-assisted thoracoscopic surgery (VATS) is still considered the optimal approach for early-stage non-small cell lung cancer. The widespread application of traditional one-lung ventilation (OLV) technology not only achieves effective lung isolation, but also facilitates exposure of the surgical field during thoracoscopic surgery, making it more convenient for surgeons to operate. However, the occurrence of hypoxemia during one-lung ventilation may pose a risk to patient safety.
One-lung ventilation can lead to increased intrapulmonary shunt, ventilation/perfusion (V/Q) mismatch, and ischemic-hypoxic lung injury. Hypoxemia is the major problem during one-lung ventilation. Postoperative pulmonary complications (PPCs) are among the major complications following thoracic and general anesthesia surgeries, including atelectasis, pneumonia, and respiratory failure, which significantly prolong hospital stay and increase mortality.
Low tidal volume lung-protective ventilation strategies have been widely implemented. Additionally, permissive hypercapnia, reducing peak airway pressure to minimize barotrauma, and decreasing FiO₂ all help reduce pulmonary complications.Recently, researchers have focused on optimizing ventilation strategies during OLV, such as using PEEP or low VT ventilation alone or in combination, or exploring different combinations of tidal volume and respiratory frequency under consistent minute ventilation (VE), aiming to balance lung protection and oxygenation, reduce complications, and improve patient outcomes.
However, to date, there is still no gold standard tidal volume ventilation strategy for reducing pulmonary complications in patients undergoing lung resection.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age > 50 years.
ASA physical status I-II.
The cardiopulmonary and other vital organ functions are basically normal, and the patient is able to tolerate surgery.
Ariscat score > 26.
Disqualifiers
Patients who refuse to participate in the clinical trial, or have cognitive impairment or impaired ability to understand and express themselves.
ASA physical status ≥ III.
Patients with congestive heart failure, severe aortic stenosis, or extensive pleural adhesions.
Patients with severe psychiatric disorders or allergy to anesthesia-related medications.
Trial population
Patients undergoing video-assisted lung surgery
Trial design
Cohort
Prospective
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
Postoperative Pulmonary Complications (PPCs)
Postoperative Pulmonary Complications (PPCs): Incidence of any PPC within 7 days postoperatively
Secondary outcomes
Incidence of hypoxemia
Incidence of hypoxemia: Occurring before the end of surgery
Length of Hospital Stay
Length of Hospital Stay
Other outcomes
Intraoperative Oxygenation Index
Intraoperative Oxygenation Index
Intraoperative Lung Compliance
Intraoperative Lung Compliance
Intraoperative Driving Pressure
Intraoperative Driving Pressure
Intraoperative Dead Space to Tidal Volume Ratio (Vd/Vt)
Intraoperative Dead Space to Tidal Volume Ratio (Vd/Vt)
Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: